Based on our study and the above clinical reports of first-generation EGFR TKIs, we suggested that the inappropriate regimen design was the main cause for the recently neglectable improvement of osimertinib-cytotoxic chemotherapy combined treatment, in which combination group received concurrent treatment of osimertinib and carboplatin/pemetrexed in a 3-week cycle for up to four cycles [44], a schedule (P + A) that in our study had shown only addictive effect in vitro and mediocre anti-tumor effect in vivo (Fig. 1,2,3). This evidence concerns the gene EGFR and neoplasm.